US Pharmaceutical Innovation in an International Context
- 1 June 2010
- journal article
- research article
- Published by American Public Health Association in American Journal of Public Health
- Vol. 100 (6), 1075-1080
- https://doi.org/10.2105/ajph.2009.178491
Abstract
Objectives. We explored whether the United States, which does not regulate pharmaceutical prices, is responsible for the development of a disproportionate share of the new molecular entities (NMEs; a drug that does not contain an active moiety previously approved by the Food and Drug Administration) produced worldwide. Methods. We collected data on NMEs approved between 1992 and 2004 and assigned each NME to an inventor country. We examined the relation between the proportion of total NMEs developed in each country and the proportion of total prescription drug spending and gross domestic product (GDP) of each country represented. Results. The United States accounted for 42% of prescription drug spending and 40% of the total GDP among innovator countries and was responsible for the development of 43.7% of the NMEs. The United Kingdom, Switzerland, and a few other countries innovated proportionally more than their contribution to GDP or prescription drug spending, whereas Japan, South Korea, and a few other countries innovated less. Conclusions. Higher prescription drug spending in the United States does not disproportionately privilege domestic innovation, and many countries with drug price regulation were significant contributors to pharmaceutical innovation.Keywords
This publication has 16 references indexed in Scilit:
- Pharmaceutical Price Controls and Entry StrategiesThe Review of Economics and Statistics, 2007
- Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesPublished by Wiley ,2006
- Foreign free riders and the high price of US medicinesBMJ, 2005
- Examining the link between price regulation and pharmaceutical R&D investmentHealth Economics, 2004
- The New Medicare Prescription-Drug Benefit — A Pure Power PlayThe New England Journal of Medicine, 2004
- Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New ZealandForum for Health Economics and Policy, 2004
- Doughnut Holes And Price ControlsHealth Affairs, 2004
- FDA chief wants other rich countries to share drug development costsBMJ, 2003
- The pharmaceutical industry as a medicines providerThe Lancet, 2002
- Lessons from international experience in controlling pharmaceutical expenditure III: regulating industryBMJ, 1996